Faculty of Dentistry, Cairo University
Cairo, Egypt
NCT Number: NCT06809478
The goal of this clinical trial is to evaluate whether Chitosan liquid will show similar clinical and radiographical success rate compared to Formocresol when used in vital pulp therapy in primary molars.
The main question it aims to answer is:
* Will Chitosan liquid, in comparison to Formocresol, show similar clinical outcomes in relation to presence/absence of post-operative pain, swelling, sinus and/or fistula formation when used in vital pulpotomy in primary molars? * Will Chitosan liquid, in comparison to Formocresol, show similar radiographical outcomes in relation to presence/absence of furcal involvement, periapical lesion, pathological root resorption and/or widening of periodontal membrane space when used in vital pulpotomy in primary molars?
Following conventional pulpotomy procedure, the primary investigator will evaluate the effect of placing a cotton pellet damp with Chitosan liquid directly on radicular vital pulp compared to that of placing a cotton pellet damp with Formocresol on radicular vital pulp.
Primary teeth included in both arms of the study will be restored by zinc oxide and eugenol and covered by a stainless steel crown as final restoration.
The clinical trail will be followed up for 1 year. Clinical outcomes will be evaluated every 3 months. Radiographic outcomes will be evaluated every 6 months.
Trial opening soon.
Get Notified4 year–8 year
All sexes
Interventional
Not applicable
Cairo, Egypt
The main goal of pulp therapy is to maintain the integrity and health of the teeth and their supporting tissues while ensuring the vitality of the pulp of a tooth affected by caries, traumatic injury, or other causes.
Formocresol is a favored medicament for pulp therapy due to its proven success as a fixative, disinfectant, and devitalizing agent. For the past 70 years, it has been the most popular agent for vital pulpotomy in deciduous teeth with a success rate between 70-98%. However, concerns were issued about the potential toxic, mutagenic and cytotoxic effects of formocresol use.
Chitosan is a polysaccharide obtained by alkaline de-acetylation of chitin which is a very common natural biopolymer that can be found in the exoskeleton of crustacea. Chitosan is extensively studied in medical and pharmaceutical fields due to its competitive biological properties like biocompatibility, nontoxicity, analgesic, antitumor, hemostatic, antimicrobial, and antioxidant effects that makes it very interesting to develop for application in dentistry
The aim of the study is to evaluate the clinical and radiographical efficacy of chitosan liquid as pulp medicament compared to formocresol in vital pulpotomy of lower deciduous molars.
In this clinical trial, the principal investigator will carry out all treatment procedures, and the patients will be randomly assigned to any of the intervention groups. For both interventions, informed consent will be obtained from parents/guardians of the participating children.
For both interventions (1 experimental arm group and 1 active comparator arm group):
Group I (Experimental group) pulpotomy using chitosan liquid:
Group II (Control group) pulpotomy using formocresol:
The participants are recalled for clinical evaluation at the interval of 3, 6, 9, 12 months, and recalled for radiographic evaluation at 6 and 12 months.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Chitosan Pulpotomy
Other names: Formocresol Pulpotomy
Time frame: Baseline and 3 months
Asking the patient and/or guardian to report any pain history at that time frame and/or complaint of discomfort and pain clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 6 months
Asking the patient and/or guardian to report any pain history at that time frame and/or complaint of discomfort and pain clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 9 months
Asking the patient and/or guardian to report any pain history at that time frame and/or complaint of discomfort and pain clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 12 months
Asking the patient and/or guardian to report any pain history at that time frame and/or complaint of discomfort and pain clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 3 months
Visual examination for any sign of redness or swelling of the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 6 months
Visual examination for any sign of redness or swelling of the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 9 months
Visual examination for any sign of redness or swelling of the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 12 months
Visual examination for any sign of redness or swelling of the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 3 months
Visual examination for any sign of a sinus or fistula in the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 6 months
Visual examination for any sign of a sinus or fistula in the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 9 months
Visual examination for any sign of a sinus or fistula in the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 12 months
Visual examination for any sign of a sinus or fistula in the gingiva at that time frame and clinically. Outcome measuring unit: Binary (present/absent)
Time frame: Baseline and 6 months
Radiographic evaluation by visual interpretation of DIGORA software for any furcal lesion using Furcation Involvement Scores. Possible scores range from 0 (no radiolucency) ; 1 (radiolucency between ¼ of furcation to periapical areas); 2 (radiolucency between ¼ to ½ of furcation to periapical areas); 3 (radiolucency more than ½ of furcation to periapical areas).
Time frame: Baseline and 12 months
Radiographic evaluation by visual interpretation of DIGORA software for any furcal lesion using Furcation Involvement Scores. Possible scores range from 0 (no radiolucency) ; 1 (radiolucency between ¼ of furcation to periapical areas); 2 (radiolucency between ¼ to ½ of furcation to periapical areas); 3 (radiolucency more than ½ of furcation to periapical areas).
Time frame: Baseline and 6 months
Radiographic evaluation by visual interpretation of DIGORA software for any periapical lesion, cyst formation or obliteration.
Time frame: Baseline and 12 months
Radiographic evaluation by visual interpretation of DIGORA software for any periapical lesion, cyst formation or obliteration.
Time frame: Baseline and 6 months
Radiographic evaluation by visual interpretation of DIGORA software for any internal, external, early or pathologic root resorption from periapical radiographs.
Time frame: Baseline and 12 months
Radiographic evaluation by visual interpretation of DIGORA software for any internal, external, early or pathologic root resorption from periapical radiographs.
Time frame: Baseline and 6 months
Radiographic evaluation by visual interpretation of DIGORA software for any widening in periodontal membrane space from periapical radiographs.
Time frame: Baseline and 12 months
Radiographic evaluation by visual interpretation of DIGORA software for any widening in periodontal membrane space from periapical radiographs.
Contact information is provided by the study sponsor or research team.
Cairo University
Other
Clinical and Radiographic Evaluation of Chitosan Versus Formocresol After Vital Pulpotomy of Primary Molars: a Randomized Clinical Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07675330
Carious Exposure of Pulp, Dental Pulp Diseases
Cairo, Egypt
View Trial DetailsNCT07466095
Pulpitis - Irreversible, Pulpitis - Reversible
View Trial DetailsNCT07386925
Pulpitis - Reversible, Pulpotomies on Primary Molars
Tanta, Egypt
View Trial DetailsNCT07171229
Occlusal Caries, Proximal Caries
Cairo, Egypt
View Trial Details